Skip to main content
Equibles
BTMD logo

BTMD · biote Corp. · Metrics

Track BTMD — free

Use BTMD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BTMD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.04 -0.19 (-15.45%) At close · Nov 5 Play latest call Q2 2026 earnings call transcript
Rebalance outlook locked
Market Cap
$37.36M
Shares
35.93M
Volume · Nov 5 241.04K Avg daily vol (3M) 207.44K

BTMD metrics

88 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.04
Market cap
$37.36M

Price action

20 metrics
Price change (1W)
+7.0%
Price change (30D)
+7.9%
Price change (3M)
-45.6%
Price change (6M)
-44.1%
Price change (YTD)
-52.7%
Price change (1Y)
-57.0%
Trailing year
Price change (5Y)
-87.4%
52-week high
$2.93
52-week low
$1.03
Change from 52-week high
-58.0%
Change from 52-week low
+19.4%
Annualized volatility
75.3%
Annualized volatility (3M)
88.8%
Beta
1.3
RSI (14D)
55.4
Price vs SMA 50
-3.1%
Price vs SMA 200
-32.1%
Avg volume (3M)
204,988
Relative volume
1.1
Average dollar volume
$291,067

Company

3 metrics
Sector
Healthcare
Industry
Medical Care Facilities
Shares outstanding
35.93M

Valuation

12 metrics
P / E (TTM)
12.3
Trailing earnings · reciprocal yield 8.1%
PEG ratio
—
EV / revenue
0.8×
reciprocal yield 118.8%
EV / EBITDA
8.3×
reciprocal yield 12.0%
EV / EBIT
10.5×
reciprocal yield 9.5%
P / sales
0.2×
reciprocal yield 415.3%
P / book
—
FCF yield
45.0%
TTM · current market cap
Buyback yield
—
P / FCF
2.2
reciprocal yield 45.0%
P / operating cash flow
1.8
reciprocal yield 55.1%
Earnings yield
8.5%

Historical valuation

8 metrics
P / E historical average (3Y)
11.0×
reciprocal yield 9.1%
P / E historical average (5Y)
11.0×
reciprocal yield 9.1%
EV / revenue historical average (3Y)
1.6×
reciprocal yield 61.9%
EV / revenue historical average (5Y)
1.6×
reciprocal yield 61.9%
EV / EBIT historical average (3Y)
10.3×
reciprocal yield 9.7%
EV / EBIT historical average (5Y)
10.3×
reciprocal yield 9.7%
EV / EBITDA historical average (3Y)
9.2×
reciprocal yield 10.9%
EV / EBITDA historical average (5Y)
9.2×
reciprocal yield 10.9%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
31.2%
Shareholder yield
2.6%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-11-04

Profitability

9 metrics
Gross margin
—
Operating margin
8.0%
Trailing 12 months
Net margin
2.0%
Gross profit (TTM)
—
Operating profit (TTM)
$14.75M
Net income (TTM)
$3.73M
Trailing 12 months
Diluted EPS (TTM)
$0.10
FCF margin
10.8%
Effective tax rate
31.0%

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.76

Growth

11 metrics
Revenue growth YoY
-9.5%
Year over year
Net income growth YoY
-306.1%
Revenue (TTM)
$183.53M
Trailing 12 months
EPS growth YoY
-330.0%
Shares change YoY
-9.8%
Year over year · fewer shares
Revenue CAGR (3Y)
+5.2%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
3.7%
Debt / equity
—
Current ratio
1.4
EBITDA (TTM)
$18.60M
Free cash flow (TTM)
$19.87M
Quick ratio
0.8
Interest coverage
—
Net debt / EBITDA
5.9
Return on invested capital
22.9%
Trailing 12 months
Net cash
−$110.33M
Latest balance sheet
Cash & equivalents
$11.17M
Total assets
$101.70M
Total debt
$121.50M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$24.37M
Capital expenditures (TTM)
$4.50M
R&D (TTM)
—
SG&A (TTM)
$111.11M
Stock compensation (TTM)
$8.34M
R&D / revenue
—
Stock compensation / revenue
4.5%

Ownership (13F)

9 metrics
13F filers
71
13F filer change QoQ
-13
Institutional ownership
36.6%
Conviction holders (share of 13F filers)
1.4%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+5.2%
Holder tenure
10.3
Price vs estimated holder cost
-60.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
5.6%

Short interest

3 metrics
Short interest
3.3%
Latest settlement · 7.5 days to cover
Days to cover
7.5d
Short-squeeze score
63 / 100

Insider activity

2 metrics
Net insider buying (90D)
$202,204
Insider-sentiment score
85 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1819253 CUSIP 090683103 13F (30d) 19 filings 12 filers Visit website Investor relations